Culver City-based, NantHealth, Launches $1B Clinical Operating System (cOS)

(cOS) is an open, cloud-based platform for collecting and processing data to help deliver safer, more accountable care.

From MedCity News:

“Culver City, Calif.-based NantHealth is backed by a $1 billion from pharmaceutical magnate Dr. Patrick Soon-Shiong, and represents the rollup of eight legacy companies started or purchased by Soon-Shiong. It officially launched in January after nearly two years in stealth mode under Soon-Shiong’s NantWorks umbrella.

The company announced its presence at HIMSS in Orlando, Fla., Monday by unveiling the NantHealth Clinical Operating System (cOS), an open, cloud-based platform for collecting and processing data to help deliver safer, more accountable care. NantHealth is positioning cOS as the “centerpiece” of this massive investment…


L.A. Story: Santa Monica Takes the Startup World by Storm

According to Fast Company, 35.9 percent of all Los Angeles startups are headquartered in Santa Monica

From HuffPo:

“The current epicenter of L.A.’s startup scene is Santa Monica (population 98,000), an 8.3 square mile stretch of beachside now known as Silicon Beach. According to Fast Company, 35.9 percent of all Los Angeles startups are headquartered in Santa Monica, including the popular app, Snapchat.

With its’ great weather, beautiful people, and pedestrian-friendly streets lined with a generous selection of bars and restaurants (450 of them, to be exact), Santa Monica offers young entrepreneurs high livability and a supportive tech environment.

Santa Monica also has a burgeoning incubator and accelerator scene. Within a 12 block area, there are 15 different co-working spaces, accelerators, and incubators, including ROC, CrossCampus, General Assembly, and CoLoft. Demand is growing so fast that CrossCampus is moving from its 11,000-square-foot space at 820 Broadway to a 13,000 square-foot-property at 10th Street and Colorado Avenue after the first of the year…”

Fast Company – Analysis: LA’s Tech Scene [web]

Idealab: L.A.’s Vintage Incubator

Since the incubator began, Idealab has created and operated more than 125 companies with 40 IPOs and acquisitions.

From Forbes:

“Idealab was founded in 1996 by Bill Gross to help new startups get off the ground in the Los Angeles region.

The original idea for an “idea lab” was only supposed to last one year.

“I wasn’t thinking long term. I didn’t think I’d be doing this 17 years later,” said Bill Gross, founder of Idealab, Los Angeles’ first startup incubator, which was formed in 1996.

“It was much more personal then. I had come up with ideas all my life and learned that the more focused a company can be, the more successful it can be…”

Idealab [web]

Meet Patrick Soon-Shiong, The LA Billionaire Reinventing Your Health Care

Dr. Soon-Shiong poured $800 million into 60 companies, university research programs and his own “do tanks.”

From Huffington Post:

“SANTA MONICA, Calif. –- You have been diagnosed with lung cancer.

There is a bewildering array of drugs, and combinations of drugs, that may shrink the tumor and prolong your life. Or they could make matters worse and give you terrible side effects.

In the past, this decision was mostly a crude guess, and it was often wrong.

No longer.

Now, your doctor draws blood and tissue, sends the information to a medical Big Data center that, in seconds, sequences your entire genome and, more importantly, maps how the proteins and the cells in your body are translating your specific DNA mutation into tumor cells. Your doctor then accesses a secure global “bank” of cancer DNA and tissue, and develops an individual cocktail for you, administering it with precise nanotechnology. You recover at home, monitored by high-information devices connected through transmitters to your doctor and clinic.

This is a glimpse of the future that Dr. Patrick Soon-Shiong of Los Angeles has spent a decade imagining — and is now rapidly assembling. The technology and science are all at hand, he says. It’s “just” a matter of putting them together into a logical and humane whole…”


UCLA Hosts Conference Uniting Cleantech Inventors and Investors

UCLA researchers meet investors and industry executives who can help commercialize their cleantech inventions.

From EcoSeed:

” LOS ANGELES — The University of California, Los Angeles (UCLA) Office of Intellectual Property & Industry Sponsored Research (OIP-ISR) is gathering leading innovators and investors in the cleantech industry at its Cleantech & Advanced Materials Industry Partnering Conference today at the UCLA Covel Commons. The conference exemplifies OIP-ISR’s quintessential goal of “driving innovation to market” because it is an opportunity for UCLA researchers to meet investors who can help them commercialize their cleantech products.

2013 has featured many initiatives organized by UCLA OIP-ISR that illustrated its commitment to to the success of green businesses. Among these was its Entrepreneurs-in-Residence program which paired UCLA students, staff and faculty with executives who have invested in a variety of industries. Over the course of this three-month program, the four entrepreneurs who served in this program shared their business expertise directly with members of the UCLA family in consulting roles and to the general public through OIP-ISR’s STARTUPS 101 seminar programs. This group of entrepreneurs included UCLA alumna Sandra Itkoff, a renowned cleantech investor who has also advised cleantech entrepreneurs at the newly formed Los Angeles Cleantech Incubator.

One of the OIP-ISR conference’s faculty speakers, UCLA Smart Grid Energy Research Center (SMERC) Founding Director and Mechanical and Aerospace Engineering Professor Dr. Rajit Gadh, shared a brief overview of the presentation he will be giving on electric vehicle (EV) technology in a September 2013 email message…”

SMERC [web]
LA Cleantech Incubator [web]

SoCalGas Establishes $1M Innovation Fund To Speed Development Of Clean Technologies

Los Angeles Cleantech Incubator Boosts Utility’s Research & Development

From WSJ:

“LOS ANGELES, Sept. 5, 2013 /PRNewswire/ — Southern California Gas Company (SoCalGas) has established a $1 million innovation fund with the Los Angeles Cleantech Incubator (LACI) to speed the development of clean technologies.

Working in collaboration with the LACI, a nonprofit business development agency that helps accelerate the commercialization of clean technologies, SoCalGas has launched an effort to identify and help bring to market potential clean technology solutions in three key areas: fuel cells, renewable natural gas and distributed natural gas products such as liquid transportation fuels and other chemicals.

“Natural gas is more than just a bridge fuel to meet current global energy needs; it has the potential to become a truly sustainable energy source, through new technologies that can produce gas from biomass and solar energy. We are excited about the project with LACI because it enables us to speed the advancement of key technology areas that we think can have a significant impact on the environmental issues facing California and the planet,” said Jeff Reed, Director of Business Strategy and Development for SoCalGas. “This collaboration provides us with a very cost effective and streamlined solution to identifying, developing and deploying strategic technologies.”

Los Angeles Cleantech Incubator [web]

Incubating LA’s Biotech Future, With Richard Koffler, Greenwings Biomedical

Our mission is to bring inventions and innovation out of research institutions, primarily Universities, and license them and convert those inventions and innovations into viable products, and eventually companies, which we can get acquired for an early exit, or launch them into commercial operation and then eventually get acquired.

From SocalTECH:

“A couple of weeks ago, a brand new, startup incubator launched in town–with a slightly different focus, on biomedical technology. The incubator–Greenwings Biomedical (, is led by Richard Koffler, a serial entrepreneur and angel investor in Los Angeles. Koffler tells us why Greenwings isn’t just another accelerator –and instead, is internally incubating companies based on research from local universities. He sat down with us to tell us more about the incubator, plus why–having started an equivalent of what would be called accelerator today, but during the dot com days–he’s a fan of a different model today.

Why did you decide to start Greenwings?
Richard Koffler: I’ve done this before. I was involved in the healthcare industry with a company that I ran, and eventually sold, in healthcare information systems and telemedicine. After we sold that business, I started an incubator during the dot-com bubble. That ended up being the wrong model. It consisted of what today would be called an accelerator, which involves sprinkling a few dollars and coaching on other people. It was a failure. I think it’s very difficult to find success on that model. It was also focused on consumer internet, which was not my strength. My strength lies in hard science and engineering. Three years ago, I started the first of three companies in a portfolio out of the UCLA health system, VAL9000. I then started another project, based on an invention out of the USC biomedical engineering department, a company developing an ultrasound device used for cardiac monitoring. Finally, I started a third project out of the USC Keck School of Medicine, using software to optimize drug dosages for individuals. That is aimed at personalized medicine.

I had this portfolio of projects, and they were all making great progress, and I realized that I had already extended myself, and needed to bring it up a notch. So, I create the concept and company called Greenwings Biomedical, to help scale out that model and capacity, both in terms of manpower, talent, and financials. I think we’re doing this the right way with this incubator, as opposed to what I had tried many years ago. Plus, with biomedical companies, you have the opportunity to make a positive difference in the world. The devices and technologies you are working on can affect the delivery of medicine and increase the wellness of the population on a global basis. Any good, biomedical products has the opportunity to make a big difference to lots of people, and can also be financially lucrative. Everyone wins…”

Greenwings Biomedical [web]